$PCSA
Processa Pharmaceuticals, Inc. Stock $pcsa

$pcsa Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223040472 Filed on November 13, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.149M	$1.020M	$2.920M
YoY Change	-56.25%	-65.07%	118.24%
% of Gross Profit
Research & Development	$1.321M	$1.152M	$3.137M
YoY Change	-55.64%	-63.28%	105.47%
% of Gross Profit
Depreciation & Amortization	$220.00	$0.00	$197.1K
YoY Change	-99.89%	-100.0%	0.72%
% of Gross Profit
Operating Expenses	$2.469M	$1.152M	$3.137M
YoY Change	-57.42%	-63.28%	2.49%
Operating Profit		-$2.168M	-$6.057M
YoY Change		-64.21%	94.67%
Interest Expense	$64.52K	$90.00K	$36.71K
YoY Change	16.19%	145.16%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$2.405M	-$2.080M	-$6.020M
YoY Change	-81.52%	-65.45%	93.6%
Income Tax
% Of Pretax Income
Net Earnings	-$2.405M	-$2.082M	-$6.020M
YoY Change	-81.52%	-65.42%	101.54%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.08	-$0.37
Diluted Earnings Per Share	-$1.71	-$0.08	-$371.6K
COMMON SHARES
Basic Shares Outstanding	24.63M shares	24.53M shares	15.86M shares
Diluted Shares Outstanding		27.00M shares	16.20M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.706M	$6.860M	$9.055M
YoY Change	-27.64%	-24.24%	-52.58%
Cash & Equivalents	$4.706M	$6.900M	$9.055M
Short-Term Investments
Other Short-Term Assets	$926.3K	$1.050M	$1.832M
YoY Change	-50.81%	-42.69%	21.61%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$5.633M	$7.907M	$10.89M
YoY Change	-32.84%	-27.37%	-47.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$148.6K	$2.694K
YoY Change	-34.7%
Goodwill
YoY Change
Intangibles			$7.465M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.540K	$172.6K	$7.718M
YoY Change	0.09%	-97.76%	139210.11%
Total Long-Term Assets	$154.1K	$175.3K	$7.718M
YoY Change	-33.88%	-97.73%	-7.63%
TOTAL ASSETS
Total Short-Term Assets	$5.633M	$7.907M	$10.89M
Total Long-Term Assets	$154.1K	$175.3K	$7.718M
Total Assets	$5.787M	$8.083M	$18.60M
YoY Change	-32.87%	-56.55%	-35.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$311.6K	$346.3K	$311.1K
YoY Change	-4.86%	11.33%	-12.37%
Accrued Expenses	$229.9K	$202.2K	$216.4K
YoY Change	-42.96%	-6.55%	-54.1%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$730.6K	$826.1K	$1.193M
YoY Change	-26.84%	-30.74%	-2.75%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$66.91K	$90.00K	$171.7K
YoY Change	-55.56%	-47.59%	-57.99%
Total Long-Term Liabilities	$66.91K	$90.00K	$171.7K
YoY Change	-55.56%	-47.59%	-57.99%
TOTAL LIABILITIES
Total Short-Term Liabilities	$730.6K	$826.1K	$1.193M
Total Long-Term Liabilities	$66.91K	$90.00K	$171.7K
Total Liabilities	$797.5K	$914.8K	$1.364M
YoY Change	-30.6%	-32.95%	-24.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$75.40M	-$73.00M	-$51.20M
YoY Change	17.45%	42.58%
Common Stock	$80.66M	$80.43M	$68.78M
YoY Change	12.0%	16.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$300.0K	$300.0K	$300.0K
YoY Change	0.0%	0.0%
Treasury Stock Shares			100.0K shares
Shareholders Equity	$4.989M	$7.168M	$17.24M
YoY Change
Total Liabilities & Shareholders Equity	$5.787M	$8.083M	$18.60M
YoY Change	-32.87%	-56.55%	-35.9%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$2.405M	-$2.082M	-$6.020M
YoY Change	-81.52%	-65.42%	101.54%
Depreciation, Depletion And Amortization	$220.00	$0.00	$197.1K
YoY Change	-99.89%	-100.0%	0.72%
Cash From Operating Activities	-$2.123M	-$1.760M	-$2.974M
YoY Change	-14.98%	-40.83%	91.54%
INVESTING ACTIVITIES
Capital Expenditures	$2.780K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$2.780K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-31.28K	-50.00K	-35.25K
YoY Change	-41.63%	41.84%	-80.96%
NET CHANGE
Cash From Operating Activities	-2.123M	-1.760M	-2.974M
Cash From Investing Activities	-2.780K	0.000
Cash From Financing Activities	-31.28K	-50.00K	-35.25K
Net Change In Cash	-2.157M	-1.810M	-3.010M
YoY Change	-15.43%	-39.86%	73.16%
FREE CASH FLOW
Cash From Operating Activities	-$2.123M	-$1.760M	-$2.974M
Capital Expenditures	$2.780K	$0.00
Free Cash Flow	-$2.126M	-$1.760M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001533743
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	us-gaap	Depreciation Depreciation		usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense		usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts		usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	PCSA	Payments For Settlement Of Stock Awards PaymentsForSettlementOfStockAwards		usd
	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	PCSA	Operating Lease Liabilities OperatingLeaseLiabilities		usd
	PCSA	Non Cashlease Liability Net NonCashleaseLiabilityNet		usd
	PCSA	Non Cashlease Liability Net NonCashleaseLiabilityNet		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39531
	dei	Entity Registrant Name EntityRegistrantName	Processa Pharmaceuticals, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-1539785
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7380 Coca Cola Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 106
	dei	Entity Address City Or Town EntityAddressCityOrTown	Hanover
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	21076
	dei	City Area Code CityAreaCode	443
	dei	Local Phone Number LocalPhoneNumber	776-3133
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
	dei	Trading Symbol TradingSymbol	PCSA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24631474	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6860672	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6503595	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1046790	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1883134	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	7907462	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	8386729	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2694	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	167035	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	227587	usd
CY2023Q3	us-gaap	Security Deposit SecurityDeposit	5535	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	5535	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	172570	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	233122	usd
CY2023Q3	us-gaap	Assets Assets	8082726	usd
CY2022Q4	us-gaap	Assets Assets	8619851	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	82744	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	78896	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	346299	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	327548	usd
CY2023Q3	PCSA	Due To Licensor DueToLicensor	189000	usd
CY2022Q4	PCSA	Due To Licensor DueToLicensor	189000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5791	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	51	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	202236	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	403061	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	826070	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	998556	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	88777	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	150554	usd
CY2023Q3	us-gaap	Liabilities Liabilities	914847	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1149110	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24731474	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24631474	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16135400	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16035400	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	2473	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1614	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	80429556	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	72016688	usd
CY2023Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	100000	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	100000	shares
CY2023Q3	us-gaap	Treasury Stock Value TreasuryStockValue	300000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	300000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72964150	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64247561	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	7167879	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7470741	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8082726	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8619851	usd
CY2023Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1151740	usd
CY2022Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3136838	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4478793	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	8319907	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1015872	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2920280	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4508818	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6137674	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2167612	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6057118	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8987611	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14457581	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	85661	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	36708	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	271022	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	45672	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2081951	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-6020410	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8716589	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14411909	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.90
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.90
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27002908	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27002908	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16200222	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16200222	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25585222	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25585222	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15991653	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15991653	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	25485100	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	828897	usd
CY2022Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	300000	usd
CY2022Q1	PCSA	Shares Issued In Connection With Purchase Agreement Value SharesIssuedInConnectionWithPurchaseAgreementValue	450000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3227131	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	23236866	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2009369	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5164368	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	20081867	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	20081867	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3213815	usd
CY2022Q3	PCSA	Shares Withheld To Pay Income Tax On Stockbased Compensation SharesWithheldToPayIncomeTaxOnStockbasedCompensation	35247	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-6020410	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	17240025	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	17240025	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7470741	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	341504	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6352077	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4022073	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	10142249	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	319123	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1310875	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2612565	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	9159682	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	9159682	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	142894	usd
CY2023Q3	PCSA	Adjustments To Additional Paid In Capital Settlement Of Stock Awards AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards	52746	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2081951	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	7167879	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	7167879	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8716589	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14411909	usd
	us-gaap	Depreciation Depreciation	82	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	60552	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	66126	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-189000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	78113	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	591372	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	803521	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6052081	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1310875	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-836344	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-299074	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-57929	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-69420	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	18751	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	92161	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	5740	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-1772	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-70274	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-200825	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-62858	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5939478	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7107758	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2776	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2776	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6352077	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-35247	usd
	PCSA	Payments For Settlement Of Stock Awards PaymentsForSettlementOfStockAwards	52746	usd
	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	300000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6299331	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-335247	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	357077	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7443005	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6503595	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16497581	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6860672	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9054574	usd
	us-gaap	Stock Issued1 StockIssued1	450000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	238924	usd
	PCSA	Operating Lease Liabilities OperatingLeaseLiabilities	238924	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-73000000.0	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8700000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5900000	usd
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	7000000.0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6400000	usd
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	8432192	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6900000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zucL0TXrYhRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_866_z6e8TNLy3PA4">Use of Estimates</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_z5mcgVvEuIra" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_862_zMy4FdRrNTBc">Concentration of Credit Risk</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents. We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at September 30, 2023, exceeded FDIC limits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	142894	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	3213815	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	803521	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6052081	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2081951	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-6020410	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8716589	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14411909	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27002908	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27002908	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16200222	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16200222	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25585222	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25585222	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15991653	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15991653	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.90
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.90
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5798035	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2760527	shares
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2023Q3	us-gaap	Lease Cost LeaseCost	24000	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	24000	usd
	us-gaap	Lease Cost LeaseCost	73000	usd
	us-gaap	Lease Cost LeaseCost	73000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	24109	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	92356	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	70040	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	186505	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	14984	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	171521	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	82744	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	88777	usd
CY2023Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-23-040472-index-headers.html	Edgar Link	pending
0001493152-23-040472-index.html	Edgar Link	pending
0001493152-23-040472.txt	Edgar Link	pending
0001493152-23-040472-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
pcsa-20230930.xsd	Edgar Link	pending
pipe_001.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
pcsa-20230930_def.xml	Edgar Link	unprocessable
pcsa-20230930_cal.xml	Edgar Link	unprocessable
pcsa-20230930_lab.xml	Edgar Link	unprocessable
pcsa-20230930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCSA
Processa Pharmaceuticals, Inc. Stock $pcsa

2023 Q4 Form 10-Q Financial Statement

#000149315223040472 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCSA Processa Pharmaceuticals, Inc. Stock $pcsa

2023 Q4 Form 10-Q Financial Statement

#000149315223040472 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCSA
Processa Pharmaceuticals, Inc. Stock $pcsa